Pardeep S. Jhund

2006–2026 年に発表

別表記
Pardeep S Jhund
338
論文数
42,121
被引用数
98
h 指数
302
i10 指数

被引用数

Pardeep S. Jhund の年別被引用数1996 年: 被引用 3 件2003 年: 被引用 6 件2005 年: 被引用 2 件2007 年: 被引用 1 件2008 年: 被引用 1 件2009 年: 被引用 7 件2010 年: 被引用 26 件2011 年: 被引用 27 件2012 年: 被引用 38 件2013 年: 被引用 59 件2014 年: 被引用 64 件2015 年: 被引用 41 件2016 年: 被引用 74 件2017 年: 被引用 96 件2018 年: 被引用 113 件2019 年: 被引用 617 件2020 年: 被引用 1,628 件2021 年: 被引用 2,201 件2022 年: 被引用 2,138 件2023 年: 被引用 2,016 件2024 年: 被引用 3,516 件2025 年: 被引用 2,157 件2026 年: 被引用 67 件1997〜2002 年は被引用が無いため表示していません2004 年は被引用が無いため表示していません2006 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,718 件、この内訳の 17.4%イギリス: 引用元論文 1,933 件、この内訳の 9.1%イタリア: 引用元論文 1,287 件、この内訳の 6%中国: 引用元論文 1,277 件、この内訳の 6%ドイツ: 引用元論文 1,059 件、この内訳の 5%カナダ: 引用元論文 1,048 件、この内訳の 4.9%オランダ: 引用元論文 864 件、この内訳の 4.1%フランス: 引用元論文 697 件、この内訳の 3.3%スウェーデン: 引用元論文 640 件、この内訳の 3%オーストラリア: 引用元論文 594 件、この内訳の 2.8%スペイン: 引用元論文 587 件、この内訳の 2.8%日本: 引用元論文 583 件、この内訳の 2.7%
0%17.4%その他 32.9%

分野

  • Medicine91.3%
  • Biochemistry, Genetics and Molecular Biology4.5%
  • Immunology and Microbiology0.7%
  • Health Professions0.6%
  • Engineering0.5%
  • Computer Science0.5%
  • その他1.9%

トピック

  • Heart Failure Treatment and Management12.5%
  • Diabetes Treatment and Management12.2%
  • Cardiovascular Function and Risk Factors10.1%
  • Pancreatic function and diabetes3%
  • Cardiac pacing and defibrillation studies2.4%
  • Metabolism, Diabetes, and Cancer2.4%
  • その他57.4%

共著者

全論文

検索で開く
  1. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Subodh Verma, Claes Held, David L. DeMets, Kieran F. Docherty, Pardeep S. Jhund, Olof Bengtsson, Mikaela Sjöstrand, Anna-Maria Langkilde - New England Journal of Medicine 2019 被引用: 6,873

  2. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , С. Н. Терещенко, Jorge Thierer, Muthiah Vaduganathan, Orly Vardeny, Subodh Verma, Vinh Pham, Ulrica Wilderäng, Natalia Zaozerska, Erasmus Bachus, Daniel Lindholm, Magnus Petersson, Anna Maria Langkilde - New England Journal of Medicine 2022 被引用: 2,658

  3. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Adel R. Rizkala, Jianjian Gong, Victor Shi, Martin Lefkowitz - New England Journal of Medicine 2019 被引用: 2,354

  4. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

    著者: , , , , , , , , - The Lancet Diabetes & Endocrinology 2019 被引用: 1,614

  5. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

    著者: , , , , , , , , , , , , , - The Lancet 2022 被引用: 916

  6. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gustavs Latkovskis, Alex Pui‐Wai Lee, Gerard C.M. Linssen, Guillermo Llamas-Esperón, Vyacheslav Mareev, Felipe A. Martínez, Vojtěch Melenovský, Béla Merkely, Savina Nodari, Mark C. Petrie, Clara Saldarriaga, José Francisco Kerr Saraiva, Naoki Sato, Morten Schou, Kavita Sharma, Richard W. Troughton, Jacob A. Udell, Heikki Ukkonen, Orly Vardeny, Subodh Verma, Dirk von Lewinski, Л. Г. Воронков, Mehmet Birhan Yılmaz, Shelley Zieroth, James Lay‐Flurrie, Ilse van Gameren, Flaviana Amarante, Peter Kolkhof, Prabhakar Viswanathan - New England Journal of Medicine 2024 被引用: 709

  7. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox

    著者: , , , , , , , , , , , - European Heart Journal 2023 被引用: 239

  8. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2020 被引用: 437

  9. Dapagliflozin for heart failure according to body mass index: the DELIVER trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - European Heart Journal 2022 被引用: 146

  10. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials

    著者: , , , , , , , , , - The Lancet 2020 被引用: 649

  11. Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2022 被引用: 275

  12. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , E. Douglas Rooke, John Thomson, M.A. Warren, Kirsty Wetherall, Robbie S. Wilson, C.P. Hall, A Maseri, H. A. Bird, Gordon Murray, James W. Dear, Mark C. Petrie, Michael P. MacDonald, Pardeep S. Jhund, Elizabeth A. Connolly, David J. Murphy, Narinder Paul, A G Olsson, P.T. Koskinen, A. Fuat, Alexis Foster, Wendy Saywood, R.J. Barr, Lewis McConnachie, Louis F. Wilson, L. Larsen Rasmussen, A.R. McGinnis, H Birrell, M. Keiller, I.S. Bremner, Gareth Forbes, Jennifer Dumbleton, Jonathan Rhodes, Theodore Waller - The Lancet 2020 被引用: 342

  13. Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , - JAMA Cardiology 2021 被引用: 245

  14. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2019 被引用: 370

  15. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure

    著者: , , , , , , , , , , , , , , - JACC Heart Failure 2018 被引用: 440

  16. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Marc S. Sabatine, Mikaela Sjöstrand, Scott D. Solomon, Per Johanson, Peter J. Greasley, David W. Boulton, Olof Bengtsson, Pardeep S. Jhund, John J.V. McMurray - JAMA 2020 被引用: 536

  17. Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Circulation 2022 被引用: 150

  18. Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , , , - Annals of Internal Medicine 2022 被引用: 150

  19. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction

    著者: , , , , , , , , , , , , , , , , , , , , - JAMA Cardiology 2022 被引用: 122

  20. Finerenone in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial

    著者: , , , , , , , , , , , , , , , - European Journal of Heart Failure 2024 被引用: 80

  21. Heart Failure and Chronic Obstructive Pulmonary Disease: Diagnostic Pitfalls and Epidemiology

    著者: , , , , , - European Journal of Heart Failure 2009 被引用: 565

  22. Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis

    著者: , , , , , , , , , , , , , - The Lancet 2024 被引用: 132

  23. Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brenda Moura, Massimo Piepoli, Piotr Ponikowski, Amina Rakisheva, Arsen Ristić, Gianluigi Savarese, Carlo G. Tocchetti, Sophie Van Linthout, Maurizio Volterrani, Petar Seferović, Giuseppe Rosano, Andrew J.S. Coats, Antoni Bayés‐Genís - European Journal of Heart Failure 2022 被引用: 154

  24. Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum

    著者: , , , , , , , , , , , - European Journal of Heart Failure 2018 被引用: 425